WO2011111880A1 - Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3 - Google Patents

Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3 Download PDF

Info

Publication number
WO2011111880A1
WO2011111880A1 PCT/KR2010/001445 KR2010001445W WO2011111880A1 WO 2011111880 A1 WO2011111880 A1 WO 2011111880A1 KR 2010001445 W KR2010001445 W KR 2010001445W WO 2011111880 A1 WO2011111880 A1 WO 2011111880A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
tetrahydropyrido
pyrimidin
bond
Prior art date
Application number
PCT/KR2010/001445
Other languages
English (en)
Korean (ko)
Other versions
WO2011111880A9 (fr
Inventor
육종인
김현실
김남희
노경태
김수연
Original Assignee
주식회사 메디젠텍
사단법인 분자설계연구소
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 메디젠텍, 사단법인 분자설계연구소 filed Critical 주식회사 메디젠텍
Priority to PCT/KR2010/001445 priority Critical patent/WO2011111880A1/fr
Publication of WO2011111880A1 publication Critical patent/WO2011111880A1/fr
Publication of WO2011111880A9 publication Critical patent/WO2011111880A9/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a pharmaceutical composition for treating or preventing a disease caused by GSK3 migration from a cell nucleus to a cytoplasm containing a compound that inhibits the migration of GSK3 from the nucleus to the cytoplasm, and more particularly, to the cytoplasm in the nucleus.
  • the present invention relates to a pharmaceutical composition for inhibiting the growth or metastasis of cancer cells and a pharmaceutical composition for treating immunological diseases, which contain a novel compound that inhibits the migration of GSK3 to the stratum.
  • Glycogen synthase kinase-3 (GSK3) is a serine / threonine kinase and has a molecular weight of about 47 kD and phosphorylates 50 proteins.
  • GSK3 has two isoforms, GSK3 ⁇ and GSK3 ⁇ , and these genes are known to be very similar and very similar in function (Double BW & Woodgett. JR, J. Cell Sci., 116: 1175, 2003). .
  • GSK3 has numerous proteins, especially ⁇ -catenin or (1) in the course of (1) onset, (2) cancer development and progression, and (3) development of immune and chronic inflammatory diseases such as rheumatoid arthritis or It regulates the phosphorylation of proteins such as snail.
  • abnormality in signaling systems such as Wnt signaling promotes the development and progression of various diseases by increasing the half-life by inhibiting the phosphorylation of cancer-causing and metastatic activators such as ⁇ -catenin and snail by GSK3.
  • substances that promote the activity of GSK3 in cells or in the nucleus may be helpful in suppressing disease occurrence and progression by Wnt signaling.
  • increasing the activity of GSK3 can reduce the inhibition of GSK3 in the nucleus by Wnt signaling and effectively inhibit the onset and progression of many diseases caused by Wnt signaling.
  • the Axin gene has two isoforms, Axin1 and Axin2 (conductin).
  • the Axin1 and Axin2 genes are known to regulate protein phosphorylation through different transcriptional regulation processes.
  • the Axin gene acts as a negative regulator of Wnt signaling by promoting the phosphorylation of ⁇ -catenin by GSK3 and reducing its half-life (US Patent 2001 / 0052137A1).
  • FRAT-1 and FRAT-2 genes that bind to GSK3 to perform the nuclear export function of GSK3.
  • FRAT was found to be a GSK3 inhibitor, unlike Axin, which is known to promote ⁇ -catenin phosphorylation (Ciani, L. et al. , J. Cell Biol. , 164: 243, 2004; Yost, C. et al. ., Cell, 93: 1031, 1998), as well as GSK3 is different from the binding point and a binding form.
  • it is not related to Wnt at all, but knock-out of either Axin-1 or Axin-2 genes does not normally occur (Chia, IV & Costatini, F., Mol.
  • FRAT-1, -2, -3 can be knocked out in the normal occurrence (van Amerongen, R. et al. , Genes De., 19: 425, 2005) FRAT It is not yet clear what role genes play in Wnt signaling.
  • the present inventors have made diligent efforts to develop new compounds for treating diseases caused by a decrease in GSK3 concentration in the nucleus, resulting in novel compounds that inhibit GSK3 migration from the nucleus to the cytoplasm, and the compounds in the nucleus.
  • the present invention has been found to be useful in treating various diseases caused by decreasing GSK3 concentration.
  • Another object of the present invention is to provide a pharmaceutical composition for treating or preventing GSK3 migration-related diseases from the cell nucleus to the cytoplasm containing the compound as an active ingredient.
  • Another object of the present invention to provide a pharmaceutical composition for inhibiting growth and metastasis of cancer cells containing the compound as an active ingredient.
  • Still another object of the present invention is to provide a pharmaceutical composition for treating an immunological disease containing the compound as an active ingredient.
  • the bond between A and D is a single bond or a double bond
  • A is C ⁇ O, C ⁇ S, SO 2 , CHR a , O, S or NR a, or when the bond between A and D is a double bond, A Is CR a or N;
  • D When the bond between A and D is a single bond, D is CHR d or NR d, or when the bond between A and D is a double bond, D is CR d or N;
  • R a and R d are each independently hydrogen, halogen, -OH, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or-(CR 1 R 2 ) n- T 1- (CH 2 ) n T 2- (CH 2 ) n -T 3 ;
  • R 1 and R 2 are each independently hydrogen, halogen,-(CH 2 ) n -CN,-(CH 2 ) n -NO 2 ,-(CH 2 ) n -C (O) OH,-(CH 2 ) n -C (O) H,-(CH 2 ) n -OH,-(CH 2 ) n -NH 2 ,-(CH 2 ) n -C (O) NH 2 , substituted or unsubstituted alkyl, Substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted amino;
  • N 0, 1, 2, 3, 4, 5 or 6;
  • T 1 is a covalent bond, -C (O)-(CR 1 R 2 ) n- , -N (R 1 )-(CR 1 R 2 ) n- , -O- (CR 1 R 2 ) n- , -C (O) N (R 1 )-(CR 1 R 2 ) n- , -N (R 1 ) C (O)-(CR 1 R 2 ) n- , -S (O) p- (CR 1 R 2 ) n- , -S (O) p N (R 1 )-(CR 1 R 2 ) n- , -N (R 1 ) S (O) p- (CR 1 R 2 ) n- , -OC (O) N (R 1 )-(CR 1 R 2 ) n- , -OC (O) N (R 1 )-(CR 1 R 2 ) n- , -OC (O) N (R 1 )-(
  • P is 1 or 2;
  • T 2 is a covalent bond, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, pyridinyl, Pyrimidinyl, pyrazinyl, isoxazolyl, oxazolyl, oxdiazolyl, thienyl, thiazolyl, thiadiazolyl, benzimidazolyl, imidazolyl, indolyl, indazolyl, benzoisothiazolyl and benzofuranyl Substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, Substitute
  • T 3 is hydrogen, halogen,-(CR 1 R 2 ) n -CN,-(CR 1 R 2 ) n -NO 2 ,-(CR 1 R 2 ) n -C (O) OH,-(CR 1 R 2 ) n -C (O) H,-(CR 1 R 2 ) n -OH,-(CR 1 R 2 ) n -C (O) N (R 1 ) R 2 ,-(CR 1 R 2 ) n- N (R 1 ) R 2 , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted-(CR 1 R 2 ) n -Arylalkyl, substituted or unsubstituted-(CR 1 R 2 ) n -aryl, substituted or unsubstituted-(CR 1 R 2 ) n -heter
  • the bond between G and J is a single bond or a double bond
  • G When the bond between G and J is a single bond, G is CHR g or NR g , or when the bond between G and J is a double bond, G is CR g or N;
  • R g is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted non-aromatic mono- or bicyclic Ring, or-(CR 1 R 2 ) n -T 4- (CR 1 R 2 ) n -T 1- (CH 2 ) n -T 3 ;
  • T 4 is a covalent bond, phenyl, hydroxyphenyl, fluorophenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxa Substituted or unsubstituted aryl or heteroaryl single, including diazolyl, thienyl, thiazolyl, thiadiazolyl, benzimidazolyl, imidazolyl, indolyl, indazolyl, benzoisothiazolyl and benzofuranyl Or substituted or unsubstituted non-aromatic mono- or bicyclic, including bicyclic rings or piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, pyrrolidinyl or pyrazolidinyl ring
  • J When the bond between G and J is a double bond, J is CHR j or NR j , or when J and G is a double bond, J is CR j or N;
  • R j is independently hydrogen, halogen, substituted or unsubstituted alkyl, or-(CR 1 R 2 ) n -T 1- (CH 2 ) n -T 4- (CR 1 R 2 ) n -T 1 -(CH 2 ) n -T 3 ;
  • Y is Y 1 ( ) Or Y 2 ( );
  • W is CHR w or NR w or when Y is Y 2 , W is CR w or N;
  • R w is independently hydrogen, halogen,-(CR 1 R 2 ) n -CN,-(CR 1 R 2 ) n -NO 2 ,-(CR 1 R 2 ) n -C (O) OH,-( CR 1 R 2 ) n -C (O) H,-(CR 1 R 2 ) n -OH,-(CR 1 R 2 ) n -C (O) N (R 1 ) R 2 ,-(CR 1 R 2 ) n -N (R 1 ) R 2 , substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted-(CR 1 R 2 ) n -arylalkyl, substituted or Unsubstituted-(CR 1 R 2 ) n -aryl, substituted or unsubstituted-(CR 1 R 2 ) n -aryl, substituted or Unsubstituted
  • M is CHR m or NR m or when Y is Y 2 , M is CR m or N;
  • R m is independently hydrogen, halogen,-(CR 1 R 2 ) n -O-alkyl, substituted or unsubstituted alkyl, or-(CR 1 R 2 ) n -T 2- (CH 2 ) n- T 3 ;
  • R q is independently hydrogen, halogen, substituted or unsubstituted alkyl, or-(CR 1 R 2 ) n -T 1- (CH 2 ) n -T 4- (CR 1 R 2 ) n -T 1 -(CH 2 ) n -T 3 ;
  • Z is CHR z or NR z or when Y is Y 2 , Z is CR z or N;
  • R z is independently hydrogen, halogen,-(CR 1 R 2 ) n -CN,-(CR 1 R 2 ) n -NO 2 ,-(CR 1 R 2 ) n -C (O) OH,-( CR 1 R 2 ) n -C (O) H,-(CR 1 R 2 ) n -OH,-(CR 1 R 2 ) n -C (O) N (R 1 ) R 2 ,-(CR 1 R 2 ) n -N (R 1 ) R 2 , substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted-(CR 1 R 2 ) n -arylalkyl, substituted or Unsubstituted-(CR 1 R 2 ) n -aryl, substituted or unsubstituted-(CR 1 R 2 ) n -aryl, substituted or Unsubstituted
  • the present invention also provides a pharmaceutical composition for inhibiting growth and metastasis of cancer cells containing the compound represented by Formula 2, a pharmaceutically acceptable salt, prodrug, or isomer thereof as an active ingredient.
  • FIG. 1 is a schematic diagram showing the activation of ⁇ -catenin, increased Axin2 expression, and GSK3 regulation in the nucleus by Wnt signaling.
  • Figure 2 is a schematic diagram of the process of concentration control of nuclear GSK3 by nuclear signaling by Wnt signaling.
  • FIG. 3 is a schematic diagram of the binding structure of Axin and GSK3.
  • alkyl refers to a saturated straight or branched ratio having 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, most preferably 1 to 4 carbon atoms.
  • -Means a cyclic hydrocarbon.
  • saturated straight chain alkyls include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl, -n-octyl, -n-nonyl and -n-decyl, and saturated branched alkyls include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, 2 -Methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl , 2,3-dimethylpentyl, 2,4-dimethylpentyl,
  • Alkyl groups may be unsubstituted or substituted. Alkyl groups can be specified as having a certain number of carbon atoms. For example, an alkyl group having 1 to 8 carbon atoms may be specified as a C1-C8 alkyl group, while an alkyl group having 1 to 6 carbon atoms may be specified as a C1-C6 alkyl group.
  • the symbol "-" denotes the point of attachment to the rest of the molecule, wherein one of the hydrogens of the alkyl group is associated with an aryl group. It is substituted with a bond.
  • — (C 1 -C 2 alkyl) aryl includes groups such as —CH 2 Ph, —CH 2 CH 2 Ph and —CH (Ph) CH 3 .
  • alkenyl refers to an unsaturated straight or branched non-cyclic hydrocarbon having 2 to 20 carbon atoms and one or more carbon-carbon double bonds. Preferably alkenyl has 2 to 10 carbon atoms.
  • Exemplary straight-chain alkenyls include, but are not limited to, -but-3-ene, -hex-4-ene and -oct-1-ene.
  • Exemplary branched alkenyls include, but are not limited to, 2-methyl-but-2-ene, -1-methyl-hex-4-ene and -4-ethyl-oct-1-ene Can be.
  • Alkenyl groups may be substituted or unsubstituted.
  • Alkenyl groups can be specified as having a certain number of carbon atoms. For example, alkenyl groups having 2 to 8 carbon atoms can be specified as C 2 -C 8 alkenyl groups, while alkenyl groups with 2 to 6 carbon atoms can be specified as C 2 -C 6 alkenyl groups.
  • alkynyl means an alkyl group wherein one or more carbon-carbon single bonds are replaced with the same number of carbon-carbon triple bonds. Alkynyl groups must contain two or more carbon atoms and can be substituted or unsubstituted. Alkynyl groups can be specified as having a certain number of carbon atoms. For example, an alkynyl group having 2 to 8 carbon atoms may be specified as a C 2 -C 8 alkynyl group, while an alkynyl group having 2 to 6 carbon atoms may be specified as a C 2 -C 6 alkynyl group.
  • oxo means a ⁇ O group.
  • hydroxy and hydroxyl refer to an -OH group.
  • hydroxyalkyl as used herein, means an alkyl group wherein at least one hydrogen is substituted with a hydroxyl group.
  • hydroxyalkenyl as used herein refers to an alkenyl group in which one or more hydrogens are substituted with hydroxyl groups.
  • hydroxyalkynyl as used herein, means an alkynyl group in which one or more hydrogens are substituted with a hydroxyl group.
  • Alkoxy means the structure of formula -O-alkyl, wherein alkyl has the meanings described above.
  • Haloalkoxy means an alkoxy group wherein at least one hydrogen has been replaced with a halogen atom.
  • Hydroxyalkoxy means an alkoxy key in which at least one hydrogen is substituted with a hydroxy group.
  • Alkylsulfonyl means the structure of the formula -S (O) 2 -alkyl.
  • Amino refers to the -NH 2 group.
  • Alkylamino and dialkylamino refer to the structures of the formula -NH-alkyl and -N (alkyl) alkyl, respectively, wherein alkyl is as defined above.
  • the alkyl groups in the dialkylamino groups can be the same or different.
  • Alkylsulfonyl amino refers to the structure of the formula -NHS (O) 2 -alkyl.
  • Carbocyclic ring system and “carbocyclic” refer to ring systems in which all ring members are carbon atoms. Carbocyclic ring systems typically contain 3 to 14 ring atoms. Carbocyclic ring systems may be aromatic or non-aromatic. Carbocyclic ring systems include cycloalkyl rings and may also include fused ring systems. Examples of fused ring carbocyclic ring systems include, but are not limited to, decalin, norbornane, tetrahydronaphthalene, naphthalene, indene and adamantane. Ring atoms in the carbocyclic ring system may be substituted or unsubstituted.
  • heterocyclic ring refers to a carbocyclic ring system in which one or more ring atoms is a hetero atom such as N, O, S or Si.
  • the heterocyclic ring system includes 1 to 4 hetero atoms.
  • the hetero atom is selected from N, O or S.
  • Heterocyclic ring systems can include one ring or a fused ring system.
  • the heterocyclic ring system may comprise two six membered rings fused to each other, or may comprise one five membered ring and one six membered ring fused to each other.
  • Heterocyclic ring systems can be aromatic or non-aromatic, and can be unsaturated, partially unsaturated or saturated. Ring atoms in the heterocyclic ring system may be substituted or unsubstituted.
  • aryl refers to a carbocyclic ring or ring system containing 6 to 14 ring atoms wherein at least one ring is aromatic.
  • the ring atoms of the carbocyclic aryl group are all carbon atoms.
  • Aryl groups include mono-, bi- and tricyclic groups, as well as benzo-fused carbocyclic moieties such as, but not limited to, 5,6,7,8-tetrahydronaphthyl and the like.
  • the aryl group is a monocyclic ring or bicyclic ring.
  • aryl groups include, but are not limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, phenanthrenyl and naphthyl.
  • the aryl group can be unsubstituted or substituted.
  • heteroaryl means an aryl group in which one or more, but not all, ring carbon atoms in any ring that is aromatic or non-aromatic is substituted with a hetero atom.
  • pyridine is a heteroaryl group, such as a compound in which benzene is fused to a non-aromatic ring containing one or more hetero atoms.
  • exemplary hetero atoms are N, O, S and Si.
  • the hetero atom is N, O or S.
  • Heteroaryl groups can be unsubstituted or substituted.
  • Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrazolyl, 3- Pyrazolyl, 5-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-iso Sazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furanyl, 3-furanyl, dibenzofuryl, 2-thienyl (2 -Thiophenyl), 3-thienyl (3-thiophenyl), 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidiny
  • Non-limiting examples of other heteroaryl groups include pyridyl, indazolyl, isoquinolinyl, thiazolopyridinyl, benzothiazolonyl, dihydroquinolinonyl, benzoisoxazolyl, benzooxazoloyl, indolinonyl, Benzoimidazolonyl, phthalazinyl, naphthyridinyl, thienopyridinyl, benzodioxolyl, isoindolinonyl, quinazolinyl or cinnaolinyl.
  • cycloalkyl refers to an unsaturated or saturated hydrocarbon that forms one or more rings having 3 to 20 ring carbon atoms, and in some embodiments 3 to 10, 3 to 8 or 3 to 6 ring carbon atoms do.
  • the ring in the cycloalkyl group is non-aromatic. Cycloalkyl groups can be unsubstituted or substituted.
  • a compound of the present invention may be optionally substituted with one or more substituents, such as those generally exemplified above or exemplified by certain classes, subclasses and species of the present invention.
  • substituents such as those generally exemplified above or exemplified by certain classes, subclasses and species of the present invention.
  • substituted refers to the substitution of a hydrogen radical in a given structure with a radical of a specified substituent, whether or not preceded by "optionally”.
  • an optionally substituted group may have a substituent at each substitutable position of the group, and if more than one position in any given structure may be substituted with more than one substituent selected from the specified group, such substituents May be the same or different at all positions.
  • Combinations of substituents contemplated in the present invention are preferably combinations which lead to the formation of stable or chemically suitable compounds.
  • inhibiting of growth and metastasis of cancer cells means “anticancer”. That is, it means the action of inhibiting or killing the proliferation of cancer cells and the action of inhibiting or blocking the metastasis of cancer cells, and means both prevention and treatment of cancer.
  • prevention refers to any action that inhibits cancer formation or delays the onset of administration of the composition
  • treatment refers to any action that improves or advantageously changes the symptoms of the disease by administration of the composition. It means.
  • treatment includes (i) preventing the disease, disorder or symptom in a mammal that may be susceptible to disease, disorder and / or symptom but cannot yet be diagnosed with it; (ii) inhibiting a disease, disorder or symptom, ie, arresting their onset; And (iii) alleviating a disease, disorder or symptom, ie, causing regression of one or more of the disease, disorder and / or symptoms, or signs thereof.
  • prevention also specifically refers to the ability of a compound or composition of the invention to prevent such a disease in a mammal diagnosed with or at risk of developing the disease identified herein. The term also includes preventing further progression of the disease in a mammal already suffering from or having signs of the disease.
  • containing as an active ingredient is meant to contain a “therapeutically effective amount” or “prophylactically effective amount” of the compound represented by formula (2) according to the present invention, a pharmaceutically acceptable salt, prodrug or isomer thereof.
  • a “therapeutically effective amount” is a compound of the invention sufficient to provide an advantage in the treatment or prevention of a symptom or disease, such as cancer, to delay or minimize a symptom associated with the symptom or disease, or to treat or ameliorate a disease or cause thereof. Or the amount of a prodrug thereof.
  • a therapeutically effective amount means an amount sufficient to provide a therapeutic benefit in vivo.
  • prophylactically effective amount refers to an amount of a compound of the present invention or other active ingredient sufficient to prevent a symptom or disease, such as cancer, or recurrence or metastasis of the cancer.
  • a prophylactically effective amount refers to an amount sufficient to prevent the initial disease, or recurrence or spread of the disease.
  • the term “preferably” includes non-toxic amounts that improve overall prophylaxis or enhance or synergize with the prophylactic efficacy of another prophylactic or therapeutic agent.
  • the term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases, including inorganic and organic acids and bases.
  • the compound of formula (2) is a base, any suitable method available in the art, for example, treatment of the free base with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or the like, or organic acids such as acetic acid, male Acids, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acid such as glucuronic acid or galacturonic acid, alpha-hydroxy acid such as citric acid or tartaric acid, amino acids such as aspartic acid Or by treating with glutamic acid, aromatic acid such as benzoic acid or cinnamic acid, sulfonic acid such as p-toluenesulfonic
  • any suitable method is preferred, for example by treating the free acid with an inorganic or organic base such as an amine (primary, secondary or tertiary), alkali metal hydroxide or alkaline earth metal hydroxide and the like.
  • Phase acceptable salts can be prepared.
  • suitable salts include organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary and tertiary amines, and cyclic amines such as piperidine, morpholine and piperazine, and sodium, calcium, Inorganic salts derived from potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
  • the salt can be contacted with a base or acid in a conventional manner and the parent compound can be isolated to regenerate the neutral form of the compound from the salt.
  • the parent form of the compound differs from some physical properties, such as various salt forms, solubility in polar solvents, for the purposes of the present invention, the salt is equivalent to the parent form of the compound.
  • prodrug means any chemical that is converted to various therapeutically effective chemicals after administration.
  • Prodrugs of the compounds described herein are compounds that readily change chemically under physiological conditions to provide the compounds of the present invention.
  • Prodrugs may also be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, when a prodrug is present with a suitable enzyme or chemical reagent in a transdermal package reservoir, it may be slowly converted to a compound of the present invention.
  • Prodrugs are often useful because, in some cases, they may be easier to administer than the parent drug. For example, prodrugs are available in vivo by oral administration, while parent drugs are not.
  • Prodrugs may also have improved solubility in pharmaceutical compositions compared to the parent drug.
  • Various prodrug derivatives such as derivatives based on hydrolytic or oxidative activation of prodrugs, are known in the art.
  • Non-limiting examples of prodrugs will be compounds of the invention that are administered as esters ("prodrugs"), but then metabolically hydrolyzed with an active substance called carboxylic acid. Further examples include peptidyl derivatives of the compounds.
  • the compounds of the present invention may contain one or more asymmetric centers and may therefore exist in racemic and racemic mixtures, scalemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. have. All such isomeric forms of these compounds are expressly included in the present invention.
  • optically pure or “stereoisomericly pure” means a composition comprising one stereoisomer of a compound and substantially free of other stereoisomers of that compound.
  • a stereoisomerically pure compound having one chiral center will be substantially free of the opposite enantiomers of the compound.
  • a typical stereoisomerically pure compound is greater than about 80 weight percent of one isomer of the compound, less than about 20 weight percent of the other stereoisomer of the compound, more preferably greater than about 90 weight percent of one stereoisomer of the compound, Less than about 10 weight percent of stereoisomers, even more preferably more than about 95 weight percent of one stereoisomer of the compound, less than about 5 weight percent of the other stereoisomers of the compound, most preferably about 97 weight of one stereoisomer of the compound Greater than weight percent and less than about 3 weight percent of other stereoisomers of the compound.
  • the present invention encompasses the use of stereoisomericly pure forms of such compounds as well as the use of mixtures of these forms.
  • mixtures comprising the same or non-equivalent amounts of enantiomers of certain compounds of the invention can be used in the methods and compositions of the invention.
  • isomers can be synthesized asymmetrically or cleaved using standard techniques such as chiral columns or chiral splitting agents (see, eg, Jacques, J., et al, Enantiomers, Racemates and Resolution (Wiley-lnterscience). , New York, 1981); Wilen, SH, et al.
  • Some compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are within the scope of the present invention.
  • GSK3 tau protein kinase (TPK I), FA factor (Factor A) kinase, kinase FA and ATP-citrate lyase kinase (ACLK).
  • Glycogen synthase kinase 3 present in two isotypes, GSK3 ⁇ and GSK3 ⁇ , is a proline-associated serine / threonine kinase originally identified as an enzyme that phosphorylates glycogen synthase.
  • GSK3 is a glycogen synthase, phosphatase inhibitor I-2, type II subunit of cAMP-dependent protein kinase, G-subunit of phosphatase-1, acetyl coenzyme A carboxylase, myelin basic protein, microtubule- Related protein, neurofibrillary protein, M-CAM cell adhesion molecule, nerve growth factor receptor, c-Jun transcription factor, JunD transcription factor, c-Myb transcription factor, c-Myc transcription factor, L-Myc transcription factor, adenomatous It has been demonstrated to phosphorylate many proteins in vitro, such as polyposis tumor suppressor protein, tau protein and ⁇ -catenin.
  • the various proteins described above that can be phosphorylated by GSK3 mean that GSK3 is involved in a number of metabolic and regulatory processes in the cell.
  • GSK3 migration-related diseases from the nucleus to the cytoplasm include diseases mediated through GSK3, such as cancer, diabetes mellitus, Niemann Pick's disease type C, bipolar disorder ( Especially manic depression), Alzheimer's disease, FTDP-17 (frontal temporal dementia associated with Parkinson's disease), cortico-basal degeneration, progressive supranuclear palsy, multiple system atrophy, peak Pick's disease, dementia Pugilistica, AIDS associated dementia, dementia, stroke, Guam parkinsonism-dementia complex, postencephalic Parkinsonism ), Frontal lobe degeneration, argyrophilic grains disease, depression, Schizophrenia, Huntington's disease, myotonic dyst rophy), subacute sclerotizing panencephalitis, prion disease, Down's syndrome, allergic or asthma, multiple sclerosis, rheumatoid arthritis, arteriosclerosis, inflammatory bowel disease, Skin diseases such as baldness, pain
  • the signaling mechanism proposed by the present invention suggests a new therapeutic effect and concept of the ⁇ -catenin targeted therapeutic agent that has been developed or developed in the future.
  • As a method of inhibiting the activity of ⁇ -catenin it is known to inhibit the ⁇ -catenin transcriptional regulation by competitively binding to ⁇ -catenin transcription complexes, that is, LEF / TCF, CBP300 and the like. In this case, most of the drugs developed so far have been expected to induce apoptosis of cells by targeting ⁇ -catenin.
  • Wnt signaling reduces the expression of E-cadherin, increases the expression of ⁇ -catenin and Snail, and invades growth and metastasis of cancer cells.
  • Snail phosphorylation control process by ⁇ -catenin is as shown in FIG. Briefly, the expression of Axin is increased by ⁇ -catenin, and Axin binds to GSK3 in the nucleus and transfers GSK3 into the cytoplasm. This increases the expression of Snail and metastasis of cancer cells occurs.
  • 2 is a schematic diagram illustrating the GSK3 concentration control process in the nucleus by Wnt signaling.
  • the activation of ⁇ -catenin gene induces Axin2 gene expression, and the Axin2 gene binds to GSK3 present in the cell nucleus to perform the nuclear export function of GSK3, thereby reducing the concentration of GSK3 in the nucleus.
  • the expression of the Snail gene which is phosphorylated and degraded by GSK3, is increased.
  • increased expression of the Snail gene by Wnt signaling leads to invasive growth and metastasis of cancer cells and clinically leads to continuous recurrence and distant metastasis.
  • FIG. 3 shows the binding structure of Axin and GSK3, it can be seen that Axin binds to GSK3 by Axin-derived peptide fragment (370-390 amino acid sequence of hAxin2) (Dajani et al. , EMBO J. , 22: 494, 2003).
  • Axin and FRAT proteins have ⁇ -helix structure, and the intermediate hydrophobic residues bind to the groove structure of GSK3, and the compound that can competitively bind to inhibit the nuclear export function of GSK3 by Axin or FRAT.
  • Axin1 and Axin2 have very similar structures and similar functions to transfer GSK3 into the cytoplasm inside the nucleus.
  • Axin1 and Axin2 appear to have the same function, ie, very similar structure, by replacing Axin1 and Axin2 during development (Chia, IV & Cos tantini, F., Mol. Cell Biol). ., 25: 4371, 2005).
  • the present inventors have confirmed that the induction of Axin1 or Axin2 expression in cells after numerous trials and errors rapidly decreases the expression of GSK3 in the cell nucleus and consequently strongly increases the expression of the Snail protein, which is phosphorylated and degraded by GSK3.
  • the present invention has a fundamentally different concept from the development of various compounds for inhibiting existing phosphatase. That is, the compound described in the present invention is fundamentally different from the conventional phosphatase inhibition in that it increases the GSK3 kinase activity inside the cell nucleus by inhibiting the nuclear export function of GSK3 by Axin, rather than inhibiting the kinase domain. The concept is different.
  • the present inventors first analyzed the X-ray structure of GSK3-Axin2 to develop a new inhibitor that inhibits the binding of GSK3 and Axin2, and through this, the structural and functional pharmacophore of Axin2 binding to GSK3 Obtained new information on On the basis of this, 39 compounds of the final product obtained through several stages of organic chemical reaction were obtained, and their structure was confirmed through NMR and Mass experiment equipment. The pharmacological activity is for pharmacophore fitness score is ranked higher compound, expected for the selected compounds have been predicted through the docking studies, the actual pharmacological activity of the compound was confirmed by in vitro experiments screeening.
  • the present invention provides a composition for inhibiting GSK3 migration from the nucleus to the cytoplasm comprising a compound represented by the following Chemical Formula 2, a pharmaceutically acceptable salt, a prodrug, or an isomer thereof, in other words, from the nucleus to the cytoplasm.
  • the bond between A and D is a single bond or a double bond
  • A is C ⁇ O, C ⁇ S, SO 2 , CHR a , O, S or NR a, or when the bond between A and D is a double bond, A Is CR a or N;
  • D When the bond between A and D is a single bond, D is CHR d or NR d, or when the bond between A and D is a double bond, D is CR d or N;
  • R a and R d are each independently hydrogen, halogen, -OH, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or-(CR 1 R 2 ) n- T 1- (CH 2 ) n T 2- (CH 2 ) n -T 3 ;
  • R 1 and R 2 are each independently hydrogen, halogen,-(CH 2 ) n -CN,-(CH 2 ) n -NO 2 ,-(CH 2 ) n -C (O) OH,-(CH 2 ) n -C (O) H,-(CH 2 ) n -OH,-(CH 2 ) n -NH 2 ,-(CH 2 ) n -C (O) NH 2 , substituted or unsubstituted alkyl, Substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted amino;
  • N 0, 1, 2, 3, 4, 5 or 6;
  • T 1 is a covalent bond, -C (O)-(CR 1 R 2 ) n- , -N (R 1 )-(CR 1 R 2 ) n- , -O- (CR 1 R 2 ) n- , -C (O) N (R 1 )-(CR 1 R 2 ) n- , -N (R 1 ) C (O)-(CR 1 R 2 ) n- , -S (O) p- (CR 1 R 2 ) n- , -S (O) p N (R 1 )-(CR 1 R 2 ) n- , -N (R 1 ) S (O) p- (CR 1 R 2 ) n- , -OC (O) N (R 1 )-(CR 1 R 2 ) n- , -OC (O) N (R 1 )-(CR 1 R 2 ) n- , -OC (O) N (R 1 )-(
  • P is 1 or 2;
  • T 2 is a covalent bond, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, pyridinyl, Pyrimidinyl, pyrazinyl, isoxazolyl, oxazolyl, oxdiazolyl, thienyl, thiazolyl, thiadiazolyl, benzimidazolyl, imidazolyl, indolyl, indazolyl, benzoisothiazolyl and benzofuranyl Substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, Substitute
  • T 3 is hydrogen, halogen,-(CR 1 R 2 ) n -CN,-(CR 1 R 2 ) n -NO 2 ,-(CR 1 R 2 ) n -C (O) OH,-(CR 1 R 2 ) n -C (O) H,-(CR 1 R 2 ) n -OH,-(CR 1 R 2 ) n -C (O) N (R 1 ) R 2 ,-(CR 1 R 2 ) n- N (R 1 ) R 2 , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted-(CR 1 R 2 ) n -Arylalkyl, substituted or unsubstituted-(CR 1 R 2 ) n -aryl, substituted or unsubstituted-(CR 1 R 2 ) n -heter
  • the bond between G and J is a single bond or a double bond
  • G When the bond between G and J is a single bond, G is CHR g or NR g , or when the bond between G and J is a double bond, G is CR g or N;
  • R g is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted non-aromatic mono- or bicyclic Ring, or-(CR 1 R 2 ) n -T 4- (CR 1 R 2 ) n -T 1- (CH 2 ) n -T 3 ;
  • T 4 is a covalent bond, phenyl, hydroxyphenyl, fluorophenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, oxa Substituted or unsubstituted aryl or heteroaryl single, including diazolyl, thienyl, thiazolyl, thiadiazolyl, benzimidazolyl, imidazolyl, indolyl, indazolyl, benzoisothiazolyl and benzofuranyl Or substituted or unsubstituted non-aromatic mono- or bicyclic, including bicyclic rings or piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, pyrrolidinyl or pyrazolidinyl ring
  • J When the bond between G and J is a double bond, J is CHR j or NR j , or when J and G is a double bond, J is CR j or N;
  • R j is independently hydrogen, halogen, substituted or unsubstituted alkyl, or-(CR 1 R 2 ) n -T 1- (CH 2 ) n -T 4- (CR 1 R 2 ) n -T 1 -(CH 2 ) n -T 3 ;
  • Y is Y 1 ( ) Or Y 2 ( );
  • W is CHR w or NR w or when Y is Y 2 , W is CR w or N;
  • R w is independently hydrogen, halogen,-(CR 1 R 2 ) n -CN,-(CR 1 R 2 ) n -NO 2 ,-(CR 1 R 2 ) n -C (O) OH,-( CR 1 R 2 ) n -C (O) H,-(CR 1 R 2 ) n -OH,-(CR 1 R 2 ) n -C (O) N (R 1 ) R 2 ,-(CR 1 R 2 ) n -N (R 1 ) R 2 , substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted-(CR 1 R 2 ) n -arylalkyl, substituted or Unsubstituted-(CR 1 R 2 ) n -aryl, substituted or unsubstituted-(CR 1 R 2 ) n -aryl, substituted or Unsubstituted
  • M is CHR m or NR m or when Y is Y 2 , M is CR m or N;
  • R m is independently hydrogen, halogen,-(CR 1 R 2 ) n -O-alkyl, substituted or unsubstituted alkyl, or-(CR 1 R 2 ) n -T 2- (CH 2 ) n- T 3 ;
  • R q is independently hydrogen, halogen, substituted or unsubstituted alkyl, or-(CR 1 R 2 ) n -T 1- (CH 2 ) n -T 4- (CR 1 R 2 ) n -T 1 -(CH 2 ) n -T 3 ;
  • Z is CHR z or NR z or when Y is Y 2 , Z is CR z or N;
  • R z is independently hydrogen, halogen,-(CR 1 R 2 ) n -CN,-(CR 1 R 2 ) n -NO 2 ,-(CR 1 R 2 ) n -C (O) OH,-( CR 1 R 2 ) n -C (O) H,-(CR 1 R 2 ) n -OH,-(CR 1 R 2 ) n -C (O) N (R 1 ) R 2 ,-(CR 1 R 2 ) n -N (R 1 ) R 2 , substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted-(CR 1 R 2 ) n -arylalkyl, substituted or Unsubstituted-(CR 1 R 2 ) n -aryl, substituted or unsubstituted-(CR 1 R 2 ) n -aryl, substituted or Unsubstituted
  • D is NH
  • G is CR g
  • J is N
  • Y may be Y 1 .
  • W when Y is Y 1 , W is CHR w , M is NR m , and Q may be CHR q .
  • W when Y is Y 1 , W may be CHR w , M may be CHR m , and Q may be NR q .
  • A is CHR a
  • D is CR d
  • G is CR g
  • J is N
  • Y may be Y 2 .
  • the compound may be a compound according to the following examples.
  • Example 8 (Compound 73): 1-allyl-3- (4-hydroxy-6-methoxy-1,5-naphthyridin-3-yl) urea
  • Example 22 (Compound 117): 1- (4-hydroxy-6-methoxy-1,5-naphthyridin-3-yl) -3- (1- (blood
  • Example 27 (Compound 146): 4- (1- (4-nicotinoylpiperidin-1-yl) -1-oxopropan-2-yl)
  • Example 38 (Compound 166): 2- (3-Methylpiperidin-1-yl) -6- (quinolin-6-ylmethyl) -5,6,7,8-
  • Example 39 7-isobutyryl-2-morpholino-5,6,7,8-tetrahydropyrido
  • the compound is N1- (4-hydroxy-6-methoxy-1,5-naphthyridin-3-yl) piperidine-1,4-dicarboxamide, 1- (4-hydroxy -6-methoxy-1,5-naphthyridin-3-yl) -3- (2-morpholinoethyl) urea, 6- (2-methylbenzyl) -2-morpholino-5,6,7,8 Tetrahydropyrido [4,3-d] pyrimidin-4 (3H) -one, 2-methyl-6-((1-propyl-1H-benzo [d] imidazol-2-yl) methyl)- 5,6,7,8-tetrahydropyrido [4,3-d] pyrimidin-4 (3H) -one, 7- (2-hydroxy-4-methoxybenzyl) -2-methyl-5, 6,7,8-tetrahydropyrido [3,4-d] pyrimidin-4 (3H) -one, 7
  • the compounds according to the present invention are available from commercial compound library vendors such as LeadQuest, Asinex, or can be synthesized through known synthetic methods.
  • the compounds inhibit the nuclear export function of GSK3 by binding to GSK3 competitively with Axin. That is, the compounds according to the present invention inhibit GSK3 migration from the cell nucleus to the cytoplasm by binding to Axin, thereby promoting intracellular activity of GSK, or inhibiting or maintaining and increasing GSK3 concentration or activity decrease in the cell nucleus. It is useful for the treatment of diseases caused by decreasing GSK3 concentration.
  • the above-mentioned diseases related to the movement of GSK3 from the nucleus to the cytoplasm may include diseases mediated through GSK3, such as cancer, diabetes, Niemann Pick's disease type C, bipolar disorder (especially manic depression). ), Alzheimer's disease, FTDP-17 (frontal temporal dementia associated with Parkinson's disease), cortico-basal degeneration, progressive supranuclear palsy, multiple system atrophy, and peak disease ( Pick's disease, dementia Pugilistica, AIDS associated dementia, dementia, stroke, Guam parkinsonism-dementia complex, postencephalic Parkinsonism, Frontal lobe degeneration, argyrophilic grains disease, depression, Schizophrenia, Huntington's disease, myotonic dystrophy, Subacute sclerotizing panencephalitis, prion disease, Down syndrome, allergic or asthma, multiple sclerosis, inflammatory diseases such as rheumatoid arthritis, arteriosclerosis, inflammatory bowel disease, baldness, etc.
  • the compound according to the present invention inhibits the movement of GSK3 from the nucleus of the cell to the cytoplasm, thereby inhibiting the function of GSK, preventing and It can be useful for treatment. It can also be used to inhibit sperm movement and thus can be used as a male contraceptive.
  • the compounds of the present invention are useful for the prevention or treatment of cancer.
  • the compound of formula (2) or a pharmaceutically acceptable salt, prodrug, or isomer thereof can be used as a medicament.
  • the compounds can be used to prepare a medicament for treating or preventing GSK3 migration-related diseases from the nucleus to the cytoplasm. More particularly, the compounds can be used to prepare a medicament for treating or preventing immune diseases, including arthritis, and cancer.
  • the pharmaceutical composition for inhibiting the growth and metastasis of cancer cells containing the compound represented by the formula (2), a pharmaceutically acceptable salt, prodrug or isomer thereof as an active ingredient and the treatment of immune diseases It relates to a pharmaceutical composition.
  • the composition is a compound 18, 30, 35, 46, 61, 65, 70, 73 to 77, 79, 88 to 93, 115 to 119, 136, 144, 146, 150, 155, 158 to 167 It may contain.
  • the compounds according to the present invention can be usefully used to inhibit the development and progression of autoimmune and degenerative diseases such as rheumatoid arthritis as well as metastasis of cancer cells promoted by Wnt signal transduction.
  • the compounds according to the invention can be used by themselves or in the form of pharmaceutically acceptable acid addition salts or salts of metal complexes such as zinc, iron and the like.
  • the acid addition salt may be selected from the group consisting of hydrogen chloride, hydrogen bromide, sulfate, phosphate, maleate, acetate, citralate, benzoate, succinate, dried salt, ascorbate and tartalate. It is preferable.
  • compositions containing a compound according to the invention as an active ingredient may contain a pharmaceutically acceptable excipient or matrix according to conventional administration methods, dosage forms and therapeutic purposes. Mixing and dilution with a phosphorus carrier or encapsulation in a carrier in the form of a container is preferred. It can also be used in combination with other medicines that are beneficial for the treatment of other bone defects. At this time, the preparation of a physiologically acceptable protein composition having a desired pH, isotonicity, stability and the like can be used within the conventional technical scope in the field of the present invention.
  • the matrix is a biodegradable and chemical substance such as calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic acid, or polyanhydride, depending on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and contact properties; Biodegradable and biological substances such as bone or skin collagen, other pure proteins or matrix components of cells; Non-biodegradable and chemical materials such as sintered hydroxyapatite, bioglass, aluminate or other ceramics; Preference is given to using combinations of the foregoing materials such as polylactic acid, hydroxyapatite, collagen and tricalcium phosphate.
  • the present invention is not limited to the carrier.
  • Excipients in the present invention are lactose, dextrose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, magnesium stanrate, water, methylhydroxy Benzoate (methylhydroxybenzoate), propylhydroxybenzoate (propylhydroxybenzoate), talc (talc), mineral oil and the like can be used.
  • the compounds of formula (2) may be used in other conventional drugs used to treat cancer, such as platinum coordination compounds such as cisplatin or carboplatin; Taxane compounds such as paclitaxel or docetaxel; Camptothecin compounds such as irinotecan or topotecan; Anti-tumor vinca alkaloids such as vinblastine, vincristine or vinorelbine; Anti-tumor nucleoside derivatives such as 5-fluorouracil, gemcitabine or capecitabine; Nitrogen mustard or nitrosourea alkylating agents such as cyclophosphamide, chlorambucil, carmustine or romustine; Anti-tumor anthracycline derivatives such as daunorubicin, doxorubicin or idarubicin; HER2 antibodies such as trastuzumab; And anti-tumor grapephytotoxin derivatives such as etoposide or ten
  • the present invention also relates to a combination of a compound of formula 2 and another agent capable of preventing or treating cancer.
  • the combination can be used as a medicament.
  • the present invention also relates to a product containing (a) Formula (2) and (b) another agent capable of preventing or treating cancer as a combination formulation for simultaneous, separate or continuous use in the prevention or treatment of cancer.
  • Different drugs may be combined in a single formulation with a pharmaceutically acceptable carrier.
  • the compounds of formula (2) may be used in other conventional drugs used to treat inflammatory diseases such as steroids, cyclooxygenase-2 inhibitors, nonsteroidal-anti-inflammatory drugs, TNF - ⁇ antibodies, for example acetyl salicylic acid, bufexamac, diclofenac potassium, schlindax, diclofenac sodium, ketorolac tromethamol, tolmethine, ibuprofen, naproxen, naproxen sodium, triaprofenic acid, flubiprofen, mefenamic acid , Niflumic acid, meclofenamate, indomethacin, proglumetacin, ketoprofen, nabumethone, paracetamol, pyroxhamm, tenoxycam, nimesulide, phenylbutazone, tramadol, beclomethasone Dipropionate, betamethasone, beclomethasone Dipropionate, betamethasone, beclomethas
  • the present invention also relates to a combination of a compound of formula (2), a pharmaceutically acceptable salt, prodrug, or isomer and another agent capable of preventing or treating an inflammatory disease.
  • the combination can be used as a medicament.
  • the invention also provides a combination formulation for use simultaneously, separately or continuously in the prevention or treatment of an inflammatory disease, comprising: (a) a compound of formula (2), a pharmaceutically acceptable salt, a prodrug, or an isomer thereof; and (b
  • the present invention relates to a product containing another agent capable of preventing or treating an inflammatory disease.
  • Different drugs may be combined in a single formulation with a pharmaceutically acceptable carrier.
  • the present invention provides methods for treating or preventing mammals, including humans suffering from GSK3 migration-related diseases from the nucleus to the cytoplasm, more particularly immune diseases including cancer, arthritis, Alzheimer's disease, diabetes, in particular Methods of treating or preventing type 2 diabetes, or bipolar disorder, are provided.
  • the method comprises administering to a mammal, including a human, an effective amount of a compound of Formula 2 or a pharmaceutically acceptable salt, prodrug, or isomer thereof.
  • the pharmaceutical composition containing the compound according to the present invention can be prepared in a variety of formulations, it is preferable to use injectable or capsulated in a viscous form for injection into the site where the therapeutic effect is expected.
  • the dosage of the composition according to the present invention can be adjusted in consideration of the type of carrier such as the excipient or matrix used, the treatment site of the patient, the age, sex and diet of the patient, the severity of the infection, the time of administration and other clinical factors.
  • a conventionally known effective amount can be administered continuously or dividedly, in consideration of weight, to observe the therapeutic effect and to determine further administration.
  • Axin2-His cDNA was obtained by PCR amplification in A549 cells and amplified at the HindIII and BamHI sites of the pcDNA3.1-hyg (+) (invitrogen) vector.
  • Axin2-His cDNA was prepared and amplified in E. coli DH5 ⁇ to obtain pcDNA3.1-Axin2-His expression vector.
  • pcDNA3.1-Axin2-His expression vector After transfection of the episomal Axin2-His expression vector, pcDNA3.1-Axin2-His expression vector, to MCF7 cells (ATCC HTB-26), 200 ⁇ g / ml of hygromycin (hygromycin) ) was treated to obtain Axin2-His overexpressing cells.
  • Triton X-100 lysis buffer was added to the obtained Axin2-His overexpressing cells to obtain cell lysate.
  • 1000 ⁇ l of Triton X-100 lysis buffer was added to 20 ⁇ l of beads, and the procedure of precipitation for 1 minute at 2000 rpm was repeated three times.
  • 10 ⁇ M of the cell lysate and the compounds represented by the compounds 70, 75, 76, 77, 79, 93, 159, 160, and 163 of the compound according to the present invention were added to the neutralized bead, and Triton X-100 lysis buffer was added. The total volume was adjusted to 1000 ⁇ l.
  • a nitrocellulose membrane Pall Corp., NY
  • the primary antibodies were anti-conductin (Sigma) and anti-GSK3 ⁇ (BD Bioscience), and protein expression level was horseradish peroxidase (HRP) -conjugated secondary antibody and enhanced chemiluminescence (ECL) detection kit ( Intron, Korea) was used to sensitize the x-ray film.
  • HRP horseradish peroxidase
  • ECL enhanced chemiluminescence
  • the present invention has an effect of providing a composition for inhibiting the development and progression of a disease caused by the GSK3 migration from the cell nucleus to the cytoplasm, which occurs due to a decrease in the concentration of GSK3 in the nucleus.
  • the compounds according to the present invention are useful for the treatment or prevention of various diseases caused by a decrease in the GSK3 concentration in the nucleus by inhibiting the nuclear export function of GSK3 by Axin and increasing the GSK3 concentration in the nucleus.

Abstract

L'invention porte sur une préparation pharmaceutique destinée au traitement ou à la prévention de maladies causées par l'export nucléaire de GSK3, comprenant un composé inhibant l'export nucléaire de GSK3, et plus spécifiquement sur une préparation pharmaceutique inhibant la croissance ou les métastases de cellules cancéreuses, et comprenant un nouveau composé inhibant l'export nucléaire de GSK3, et sur une préparation pharmaceutique traitant les maladies auto-immunes. La préparation de l'invention inhibe l'apparition et la progression d'une maladie causée par une baisse de la concentration en GSK3 dans le noyau d'une cellule causée par l'export nucléaire de GSK3. Le composé de l'invention est utile pour traiter et ou prévenir différentes maladies en inhibant la fonction d'export nucléaire de GSK3 au moyen d'axine, et en augmentant la concentration en GSK3 dans le noyau.
PCT/KR2010/001445 2010-03-08 2010-03-08 Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3 WO2011111880A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2010/001445 WO2011111880A1 (fr) 2010-03-08 2010-03-08 Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2010/001445 WO2011111880A1 (fr) 2010-03-08 2010-03-08 Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3

Publications (2)

Publication Number Publication Date
WO2011111880A1 true WO2011111880A1 (fr) 2011-09-15
WO2011111880A9 WO2011111880A9 (fr) 2013-01-10

Family

ID=44563667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/001445 WO2011111880A1 (fr) 2010-03-08 2010-03-08 Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3

Country Status (1)

Country Link
WO (1) WO2011111880A1 (fr)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013117288A1 (fr) * 2012-02-09 2013-08-15 Merck Patent Gmbh Dérivés tétrahydro-quinazolinone comme inhibiteurs de tank et de parp
US8754085B2 (en) 2010-07-14 2014-06-17 Novartis Ag Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist
WO2014192868A1 (fr) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 Dérivé cyclique d'aminométhyl pyrimidine
US8937069B2 (en) 2012-01-13 2015-01-20 Novartis Ag Substituted pyrrolo[2,3-B]pyrazine compounds and their use
US9206182B2 (en) 2009-07-15 2015-12-08 Intellikine Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9266883B2 (en) 2013-10-25 2016-02-23 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9745311B2 (en) 2012-08-10 2017-08-29 Incyte Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
US9822131B2 (en) 2008-01-04 2017-11-21 Intellikine Llc Certain chemical entities, compositions and methods
USRE46621E1 (en) 2011-01-10 2017-12-05 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9956209B2 (en) 2014-09-26 2018-05-01 Glaxosmithkline Intellectual Property Development Limited Compounds αv β6 integrin antagonists
US10000489B2 (en) 2014-09-26 2018-06-19 Glaxosmithkline Intellectual Property Development Limited Compounds αvβ6 integrin antagonists
US10004724B2 (en) 2014-09-26 2018-06-26 Glaxosmithkline Intellectual Property Development Limited Compounds alpha v beta 6 integrin antagonists
US10023568B2 (en) 2013-03-28 2018-07-17 Glaxosmithkline Intellectual Property Development Limited Naphthyridine derivatives useful as αvβ6 integrin antagonists
US10144733B2 (en) 2014-09-26 2018-12-04 Glaxosmithkline Intellectual Property Development Limited Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases
US10213427B2 (en) 2010-12-22 2019-02-26 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10463653B2 (en) 2014-10-03 2019-11-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US10487080B2 (en) 2016-03-21 2019-11-26 Glaxosmithkline Intellectual Property Development Limited Naphthyridines as integrin antagonists
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
WO2020182990A1 (fr) * 2019-03-14 2020-09-17 Janssen Sciences Ireland Unlimited Company Dérivés de pyrimidone à cycles fusionnés destinés à être utilisés dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11820747B2 (en) 2021-11-02 2023-11-21 Flare Therapeutics Inc. PPARG inverse agonists and uses thereof
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060069097A1 (en) * 2002-10-15 2006-03-30 Dickerson Scott H Pyradazine compounds as gsk-3 inhibitors
US20060211678A1 (en) * 2004-08-02 2006-09-21 Saleh Ahmed Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
US20070129364A1 (en) * 2005-12-07 2007-06-07 Han-Qing Dong Pyrrolopyridine kinase inhibiting compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060069097A1 (en) * 2002-10-15 2006-03-30 Dickerson Scott H Pyradazine compounds as gsk-3 inhibitors
US20060211678A1 (en) * 2004-08-02 2006-09-21 Saleh Ahmed Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
US20070129364A1 (en) * 2005-12-07 2007-06-07 Han-Qing Dong Pyrrolopyridine kinase inhibiting compounds

Cited By (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9822131B2 (en) 2008-01-04 2017-11-21 Intellikine Llc Certain chemical entities, compositions and methods
US11433065B2 (en) 2008-01-04 2022-09-06 Intellikine Llc Certain chemical entities, compositions and methods
US9655892B2 (en) 2008-01-04 2017-05-23 Intellikine Llc Certain chemical entities, compositions and methods
US9216982B2 (en) 2008-01-04 2015-12-22 Intellikine Llc Certain chemical entities, compositions and methods
US9206182B2 (en) 2009-07-15 2015-12-08 Intellikine Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9522146B2 (en) 2009-07-15 2016-12-20 Intellikine Llc Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8754085B2 (en) 2010-07-14 2014-06-17 Novartis Ag Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist
US9132127B2 (en) 2010-07-14 2015-09-15 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
US10213427B2 (en) 2010-12-22 2019-02-26 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10813930B2 (en) 2010-12-22 2020-10-27 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US11312718B2 (en) 2011-01-10 2022-04-26 Infinity Pharmaceuticals, Inc. Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
USRE46621E1 (en) 2011-01-10 2017-12-05 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9840505B2 (en) 2011-01-10 2017-12-12 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
US10550122B2 (en) 2011-01-10 2020-02-04 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof
US9073932B2 (en) 2012-01-13 2015-07-07 Novartis Ag Substituted pyrrolo[2,3-B]pyrazines for the treatment of disorders and diseases
US8937069B2 (en) 2012-01-13 2015-01-20 Novartis Ag Substituted pyrrolo[2,3-B]pyrazine compounds and their use
JP2015506965A (ja) * 2012-02-09 2015-03-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｔａｎｋおよびｐａｒｐのインヒビターとしてのテトラヒドロ−キナゾリノン誘導体
WO2013117288A1 (fr) * 2012-02-09 2013-08-15 Merck Patent Gmbh Dérivés tétrahydro-quinazolinone comme inhibiteurs de tank et de parp
CN104093714B (zh) * 2012-02-09 2016-08-24 默克专利股份公司 作为tank和parp抑制剂的四氢-喹唑啉酮衍生物
TWI572593B (zh) * 2012-02-09 2017-03-01 馬克專利公司 四氫喹唑啉酮衍生物
EA026611B1 (ru) * 2012-02-09 2017-04-28 Мерк Патент Гмбх Производные тетрагидрохиназолинона в качестве ингибиторов tank и parp
CN104093714A (zh) * 2012-02-09 2014-10-08 默克专利股份公司 作为tank和parp抑制剂的四氢-喹唑啉酮衍生物
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US10131667B2 (en) 2012-06-13 2018-11-20 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11840534B2 (en) 2012-06-13 2023-12-12 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9745311B2 (en) 2012-08-10 2017-08-29 Incyte Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
US10450312B2 (en) 2013-03-28 2019-10-22 Glaxosmithkline Intellectual Property Development Limited Naphthyridine derivatives useful as alpha-V-beta-6 integrin antagonists
US10023568B2 (en) 2013-03-28 2018-07-17 Glaxosmithkline Intellectual Property Development Limited Naphthyridine derivatives useful as αvβ6 integrin antagonists
US10040790B2 (en) 2013-04-19 2018-08-07 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10947230B2 (en) 2013-04-19 2021-03-16 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US10450313B2 (en) 2013-04-19 2019-10-22 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US11530214B2 (en) 2013-04-19 2022-12-20 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9732065B2 (en) 2013-05-30 2017-08-15 Sumitomo Dainippon Pharma Co., Ltd. Cyclic aminomethyl pyrimidine derivative
JPWO2014192868A1 (ja) * 2013-05-30 2017-02-23 大日本住友製薬株式会社 環状アミノメチルピリミジン誘導体
US20160122319A1 (en) * 2013-05-30 2016-05-05 Sumitomo Dainippon Pharma Co., Ltd. Cyclic aminomethyl pyrimidine derivative
WO2014192868A1 (fr) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 Dérivé cyclique d'aminométhyl pyrimidine
US9266883B2 (en) 2013-10-25 2016-02-23 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US9896449B2 (en) 2013-10-25 2018-02-20 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US9533988B2 (en) 2013-10-25 2017-01-03 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US11944631B2 (en) 2014-04-16 2024-04-02 Infinity Pharmaceuticals, Inc. Combination therapies
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US10000489B2 (en) 2014-09-26 2018-06-19 Glaxosmithkline Intellectual Property Development Limited Compounds αvβ6 integrin antagonists
US10004724B2 (en) 2014-09-26 2018-06-26 Glaxosmithkline Intellectual Property Development Limited Compounds alpha v beta 6 integrin antagonists
US10144733B2 (en) 2014-09-26 2018-12-04 Glaxosmithkline Intellectual Property Development Limited Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases
US9956209B2 (en) 2014-09-26 2018-05-01 Glaxosmithkline Intellectual Property Development Limited Compounds αv β6 integrin antagonists
US10513517B2 (en) 2014-09-26 2019-12-24 Glaxosmithkline Intellectual Property Development Limited Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases
US10342783B2 (en) 2014-09-26 2019-07-09 Glaxosmithkline Intellectual Property Development Limited Compounds αvβ6 integrin antagonists
US10463653B2 (en) 2014-10-03 2019-11-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US10507201B2 (en) 2014-10-03 2019-12-17 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10214528B2 (en) 2015-02-20 2019-02-26 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10016438B2 (en) 2015-02-20 2018-07-10 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10632126B2 (en) 2015-02-20 2020-04-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9801889B2 (en) 2015-02-20 2017-10-31 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11667635B2 (en) 2015-02-20 2023-06-06 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11014923B2 (en) 2015-02-20 2021-05-25 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10251892B2 (en) 2015-02-20 2019-04-09 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10738048B2 (en) 2015-02-20 2020-08-11 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
US10487080B2 (en) 2016-03-21 2019-11-26 Glaxosmithkline Intellectual Property Development Limited Naphthyridines as integrin antagonists
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2020182990A1 (fr) * 2019-03-14 2020-09-17 Janssen Sciences Ireland Unlimited Company Dérivés de pyrimidone à cycles fusionnés destinés à être utilisés dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
CN113710667A (zh) * 2019-03-14 2021-11-26 爱尔兰詹森科学公司 用于治疗hbv感染或hbv诱发的疾病的稠合环嘧啶酮衍生物
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11820747B2 (en) 2021-11-02 2023-11-21 Flare Therapeutics Inc. PPARG inverse agonists and uses thereof

Also Published As

Publication number Publication date
WO2011111880A9 (fr) 2013-01-10

Similar Documents

Publication Publication Date Title
WO2011111880A1 (fr) Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3
WO2010104306A2 (fr) Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme
KR100748294B1 (ko) 프로판-1,3-디온 유도체
EP3551610B1 (fr) Inhibiteurs bicyclo[1.1.1]pentane de la double fermeture à glissière de leucine kinase (dlk) destinés au traitement de maladie
JP4926973B2 (ja) 治療化合物としての、イミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物ならびにそれらの類似体
JP2009544625A (ja) Ｒｈｏキナーゼのベンゾチオフェン阻害剤
KR20090120510A (ko) 단백질 키나제 억제제로서 유용한 아미노피리미딘
WO2021108198A1 (fr) Inhibiteurs de la protéine kinase 1 interagissant avec les récepteurs pour le traitement d'une maladie
AU2021257373B2 (en) Pyridopyrimidinone derivatives and their use as Aryl hydrocarbon receptor modulators
EA036388B1 (ru) Ингибиторы фосфатидилинозитол-3-киназы гамма
JP2022553273A (ja) 疾患の治療のための二重ロイシンジッパー（ｄｌｋ）キナーゼのビシクロ［１．１．１］ペンタン阻害剤
WO2023014006A1 (fr) Composé pour la dégradation ciblée de ras
WO2022131741A1 (fr) Composé dérivé d'isoxazolidine et son utilisation
WO2007051095A1 (fr) Sels de modulateurs de ppar et procedes de traitement de troubles metaboliques
WO2019027117A1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter le cancer contenant un inhibiteur du récepteur tyrosine kinase en tant que principe actif
WO2022182029A1 (fr) Dérivé d'imidazopyridine et composition pharmaceutique le comprenant en tant que principe actif
WO2021060888A2 (fr) Composition pour prévenir ou traiter le cancer, contenant un dérivé à base de trifluorométhylphényl pyrazole comme principe actif
WO2023068881A1 (fr) Dérivé aryle ou hétéroaryle, et composition pharmaceutique le comprenant en tant que principe actif pour la prévention ou le traitement de maladies associées aux kinases
WO2022263548A1 (fr) 1h-pyrrolo [2,3-b] pyridine substituée en position 3 en tant que modulateurs de grk5
EP4221708A1 (fr) Inhibiteurs imidazopipérazines de protéines d'activation de la transcription
EP4221709A1 (fr) Inhibiteurs imidazopipérazine de protéines d'activation de la transcription
CN101522643A (zh) 二环杂芳族化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10847514

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10847514

Country of ref document: EP

Kind code of ref document: A1